Considering that all tumor cells in an IDH mutant tumor carry the IDH mutation, it is not surprising that therapies targeting mutant IDH have been developed, both in the form of vaccinations12 and small molecules which inhibit mutant IDH13. This evidence concerns the gene IDH2 and neoplasm.